Clin Osteol 2017; 22(2): 56-62
Glucocorticoid-induced osteoporosis - a medical and legal issueCase reports
Glucocorticoid-induced osteoporosis is the most frequent secondary and iatrogenic cause of bone loss, often with a very rapid and disabling course and permanent consequences. Given the fact that glucocorticoids are extensively prescribed by various specialists (e.g. neurologists, rheumatologists, dermatologists, allergologists, nephrologists, endocrinologists, gastroenterologists and oncologists), the presented case reports should teach and warn. Prior to initiation of corticoste roid therapy, a possibility ofthis complication must be considered, bone densitometry performed, preventive calcium and vitamin D supplementation administered and further monitoring planned. Alternatively, the patient may be referred to a specialized center. Otherwise, potentially painful legal consequences may be expected, which are analyzed in the se cond part of the article.
Keywords: osteoporosis, glucocorticoids, prevention, consequences Osteologický bulletin 2017, 22(2)56-62
Published: December 11, 2017 Show citation
References
- Kanis JA, Johansson H, Oden A et al. A meta analysis of prior c costeroid use and fracture risk. J Bone Miner Res 2004;19:893-899.
Go to original source... - Van Staa TP, Leufkens HG, Abenhaim L et al. Us roids in the United Kingdom. QJM 2000;93:105-111. Go to original source...
- Israel E, Banerjee TR, Fitzmaurice GM et al. Effects of inhaled glu corticoids on bone density in premenopausal women. NEJM 2001; 345:941-947. Go to original source...
- Van Staa TP, Leufkens HG, Abenheim L et al. Use of oral corticoste roids and risk of fractures. J Bone Miner Res 2000;15:993-1000. Go to original source...
- Angel A, Guglielmi G, Dovio A et al. High prevalence of asymptoma tic vertebral fractures in postmenopausal women receiving chronic g cocorticoid therapy- a cross sectional outpatient study. Bone 2006; 39:253-259. Go to original source...
- O'Brien CA, Jia D, Plotkin LI et al. Glucocorticoids act directly osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004;145:1835-1841. Go to original source...
- Ton FN, Gunawardene SC, Lee H et al. Effects of lowne on bone metabolism. J Bone Miner Res 2005;20:464-470. Go to original source...
- Rubin MR, Bilezikian JP. Clinical review 151: The role of parathyr hormone in the pathogenesis of glucocorticoid induced osteoporosis a reexamination of the evidence. J Clin Endocrinol Metab 2002;87:4033-4041. Go to original source...
- Doga M, Bonadonna S, Giustina A Glucocorticoids and bone-cellular, metabolic and endocrine effects. Hormones 2004;3:184-190. Go to original source...
- Giustina A, Veldhuis JD. Pathophysiology of the neuroregul growth hormone secretion in experimental animals and in human. Endocr Rev 1998;19:717-797. Go to original source...
- Recommendations for the prevention and treatment of glucoc induced osteoporosis: 2001 update. American College of Rheuma tology. Arthritis Rheum 2001;44:1496-1503.
- Royal College of Physicians. Glucocorticoid induc guidelines for prevention and treatment. London 2002.
- Weinstein RS. Glucocorticoid induced bone disease. Primer on the Metabolic Bo 2013, p 475. Go to original source...